phrykt

Novavax Inc (NVAX): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of NVAX were reported in the last 12 months. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Novavax

From the latest filings

Overall: more selling than buying. Famous investors mostly sold. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns NVAX

265 funds and institutions reported NVAX shares worth $1.1B at the end of Q2 2026, about 72% of the company. The largest holder is Shah Capital Management with 8.6%.

Funds and institutions (13F) 72%Everyone else 28%

10 largest owners, by share of the company

Shah Capital Management8.6%
BlackRock, Inc.8.5%
State Street Corp7.1%
Vanguard Portfolio Management LLC4.6%
Vanguard Capital Management LLC4.4%
Sanofi4.2%
D. E. Shaw & Co., Inc.3.4%
Geode Capital Management, LLC2.6%
Two Sigma Investments, LP2.5%
Coatue Management LLC2.3%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Shah Capital Management14.17M8.61%$133M-5%
BlackRock, Inc.13.95M8.48%$131M+9%
State Street Corp11.74M7.14%$111M+31%
Vanguard Portfolio Management LLC7.61M4.63%$71.7M+6%
Vanguard Capital Management LLC7.26M4.41%$68.4M+2%
Sanofi6.88M4.18%$64.8MNo change
D. E. Shaw & Co., Inc.5.65M3.44%$53.2M-27%
Geode Capital Management, LLC4.21M2.56%$39.6M+8%
Two Sigma Investments, LP4.09M2.49%$38.5M+565%
Coatue Management LLC3.84M2.33%$36.1MNo change
Bank of America Corp3.42M2.08%$32.2M-49%
Goldman Sachs Group Inc3.01M1.83%$28.3M+113%
UBS Group AG1.87M1.14%$17.6M-58%
Millennium Management LLC1.77M1.08%$16.7M-54%
Citadel Advisors LLC1.70M1.03%$16M+51%
Allianz Asset Management GmbH1.58M0.96%$14.9M-15%
Northern Trust Corp1.45M0.88%$13.6M-4%
TSP Capital Management Group, LLC1.42M0.86%$13.4M–
Charles Schwab Investment Management Inc1.35M0.82%$12.7M-2%
Sixth Street Partners Management Company, L.P.1.35M0.82%$12.7M–

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

No NVAX insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

NVAX short interest

Very high short interest. 28.1% of NVAX shares are sold short: about 1 share in 4. Over the last 12 reports the number of shares short went up 2%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 46.33M NVAX shares were sold short, 28.1% of the shares outstanding, down 2.2% from the report before. At the average daily volume of 6.09M shares, buying them all back would take about 7.6 trading days (days to cover).

Shares short, % of all shares

28.1%May 15Oct 3030.8%

Days to cover

7.6May 15Oct 3018.5

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202646.33M28.09%-2%6.09M7.6
Oct 15, 202647.35M28.71%+3%10.92M4.3
Sep 30, 202646.05M27.92%-8%5.71M8.1
Sep 15, 202649.88M30.24%+2%5.37M9.3
Aug 31, 202648.78M29.58%+3%5.66M8.6
Aug 14, 202647.49M28.79%+4%3.38M14.0
Jul 31, 202645.66M27.68%+4%2.75M16.6
Jul 15, 202643.82M26.65%-4%3.84M11.4
Jun 30, 202645.81M27.86%+2%4.94M9.3
Jun 15, 202645.11M27.43%-2%4.18M10.8
May 29, 202645.97M27.95%+2%5.87M7.8
May 15, 202645.28M27.54%-8%7.13M6.3

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Novavax company events

Novavax filed 8 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Oct 29, 2026AnnouncementOn October 28, 2026 Sanofi Pasteur Inc. dosed the fifth patient in its Phase 3 influenza-COVID-19 combination vaccine trial in the European Union, utilizing the Company’s COVID-19 component. Filing
  3. Aug 6, 2026ResultsReleased financial results. Filing
  4. Jun 23, 2026VoteReported shareholder vote results. Filing
  5. May 6, 2026ResultsReleased financial results. Filing
  6. Feb 26, 2026ResultsReleased financial results. Filing
  7. Jan 20, 2026AgreementEntry into Material Definitive Agreements. Filing
  8. Jan 12, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Novavax financials

Famous investors that hold NVAX

5 of the 50 well-known investors we track reported holding NVAX in their latest 13F filing. The largest position is Philippe Laffont's, worth $41.5M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Philippe Laffont · Coatue ManagementQ3 20263.84M$41.5M0.1%No change
Ken Griffin · Citadel AdvisorsQ3 20262.78M$30.1M0.0%+64%
Israel Englander · Millennium ManagementQ3 20261.06M$11.5M0.0%-40%
Paul Tudor Jones · Tudor Investment CorpQ3 202647,514$514K0.0%-62%
Jim Simons · Renaissance TechnologiesQ3 202643,200$467K0.0%-91%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named NVAX in the last 120 days.

FiledHolderFormStake
Nov 10, 2026STATE STREET CORPORATION13G5.4%
Nov 10, 2026STATE STREET CORPORATION13G5.4%
Oct 16, 2026Shah Capital Management13D/A6.4%
Oct 16, 2026Shah Capital Management13D/A6.4%
Oct 16, 2026Shah Capital Management13G6.4%
Oct 16, 2026Shah Capital Management13G6.4%

Questions about Novavax Inc (NVAX) stock

Who owns the most NVAX stock?

The largest reported owner of Novavax Inc (NVAX) is Shah Capital Management, with 8.6% of the company. In total, 265 funds and institutions reported holding NVAX at the end of Q2 2026, together about 72% of the shares. See the largest owners.

Are NVAX insiders buying or selling?

No NVAX insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in NVAX?

As of Oct 30, 2026, 46.33M NVAX shares were sold short, 28.1% of the shares outstanding, down 2.2% from the report before. At the average daily volume of 6.09M shares, buying them all back would take about 7.6 trading days (days to cover). See the history.

Which famous investors hold NVAX?

5 of the 50 well-known investors we track reported NVAX in their latest 13F filing, including Philippe Laffont, Ken Griffin, Israel Englander. The largest position is worth $41.5M. See all holders.

Executive pay

Novavax's chief executive was paid a total of $8.9M for the year ended Dec 31, 2025. In the last 12 months, Novavax's executives and directors bought no stock on the open market and sold none.

Chief executive, total pay$8.9MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$6.3MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$2.7MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.